Abstract
Colon cancer is the second leading cause of cancer-related death in industrialized countries. Many anti-cancer researches are consequently performed and individualized tumor response testing (ITRT) methods are now used to individualize patient chemotherapeutic administrations. Then, a new ITRT method, Oncogramme, was developed for colon cancer. Colon tumor fragments from different patients were dissociated and seeded in a defined culture medium. Cell preparation process as well as culture medium allowed high cell viability and a good primary culture success rate. After treatment of isolated tumoral cells by chemotherapeutics alone or in combination, cytotoxicity was determined by cell death assay allowing the Oncogramme establishment, which was validated by statistical analysis. Indeed, significant results were obtained such as different profile for each patient’s cells with various drugs, and variability between patient’s cells in the response to each drug. Procedure described here to obtain the Oncogramme is a new, fast and technically reliable ITRT method applied to colon cancer. For an individualized cancer treatment use, this test should be further validated by a phase I clinical trial.
This is a preview of subscription content, log in via an institution to check access.
References
Angelopoulos S, Kanellos I, Sapidis N, Vasiliadis K, Kanellou A et al (2004) Survival after curative resection for rectal cancer by the end of the 20th century. Tech Coloproctol 8(Suppl 1):s167–s169
Battu S, Rigaud M, Beneytout JL (1998) Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL.19A. Anticancer Res 18:3579–3583
Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE (1981) Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41:1751–1756
Brattain MG, Levine AE, Chakrabarty S, Yeoman LC, Willson JK et al (1984) Heterogeneity of human colon carcinoma. Cancer Metastasis Rev 3:177–191
Collectif (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced colorectal cancer meta-analysis project. J Clin Oncol 10:896–903
Cortazar P, Gazdar AF, Woods E, Russell E, Steinberg SM et al (1997) Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res 3:741–747
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676
Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781
Hamburger AW (1981) Use of in vitro tests in predictive cancer chemotherapy. J Natl Cancer Inst 66:981–988
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30
Kawamura H, Ikeda K, Takiyama I, Terashima M (1997) The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer 33:960–966
Kubota T, Weisenthal L (2006) Chemotherapy sensitivity and resistance testing: to be “standard” or to be individualized, that is the question. Gastric Cancer 9:82–87
Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA et al (1998) Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 9:51–57
Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ et al (2003) Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189:1301–1307
Massaro EJ, Elstein KH, Zucker RM, Bair KW (1989) Limitations of the fluorescent probe viability assay. Mol Toxicol 2:271–284
Möllgård L, Prenkert M, Smolowicz A, Paul C, Tidefelt U (2003) In vitro chemosensitivity testing of selected myeloid cells in acute myeloid leukemia. Leuk Lymphoma 44:783–789
Paraskeva C, Corfield AP, Harper S, Hague A, Audcent K et al (1990) Colorectal carcinogenesis: sequential steps in the in vitro immortalization and transformation of human colonic epithelial cells (review). Anticancer Res 10:1189–1200
Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW et al (1990) In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 76:2327–2336
Tournigand C, André T, Achille E, Lledo G, Flesh M et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237
Vincan E, Brabletz T, Faux MC, Ramsay RG (2007) A human three-dimensional cell line model allows the study of dynamic and reversible epithelial-mesenchymal and mesenchymal-epithelial transition that underpins colorectal carcinogenesis. Cells Tissues Organs 185:20–28
Williams AC, Hague A, Manning AM, Van der Stappen JW, Paraskeva C (1993) In vitro models of human colorectal cancer. Cancer Surv 16:15–29
Wils J (2001) Adjuvant therapy for colon cancer: the European experience. Tumori 87:S85
Acknowledgments
The authors thank Professor F. Labrousse and Professor F. Paraf, Department of Anatomy and Pathology, Hospital Dupuytren, Limoges, for providing specimens.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Loum, E., Giraud, S., Bessette, B. et al. Oncogramme, a new individualized tumor response testing method: application to colon cancer. Cytotechnology 62, 381–388 (2010). https://doi.org/10.1007/s10616-010-9298-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-010-9298-5